Senior Correspondent, London
Ben's Feed
Jan 12, 2015

J&J strikes Alzheimer’s research deal with Swiss firm AC Immune

LONDON/ZURICH (Reuters) – Johnson & Johnson boosted its research efforts into battling Alzheimer’s on Monday, striking a deal potentially worth more than $500 million to develop anti-tau vaccines with Swiss biotech firm AC Immune.

Tau is a protein known for forming twisted fibers inside brain cells and is linked to cell death. It is one of two abnormal proteins tied to the memory-robbing disease. The other is beta amyloid.

Jan 12, 2015
Jan 11, 2015
Jan 11, 2015

Shire to buy NPS for $5.2 billion to boost rare disease drugs

LONDON (Reuters) – Shire Plc has agreed to buy NPS Pharmaceuticals Inc for $5.2 billion in its biggest acquisition yet, as the Dublin-based drugmaker strengthens its position in the lucrative field of medicines for rare diseases.

The takeover continues the breakneck pace of deal-making seen in 2014 in the pharmaceuticals sector, where companies are jockeying for promising assets as a wave of new drugs emerges from research laboratories.

Jan 9, 2015
Jan 9, 2015
Jan 9, 2015
Jan 8, 2015

GW Pharma’s cannabis drug fails in cancer pain study, shares fall

LONDON (Reuters) – An experimental cannabis drug failed to alleviate pain in cancer patients as hoped in a clinical study, sending shares in its British maker GW Pharmaceuticals as much as 21 percent lower on Thursday.

GW, which is developing the drug Sativex for pain in collaboration with Japan’s Otsuka, said the first of three late-stage trials found no statistically significant difference between subjects using its product and those given a placebo.

Jan 8, 2015
Jan 8, 2015
    • About Ben

      "Ben Hirschler is European pharmaceuticals, biotechnology and healthcare correspondent, based in London. Previously, he was in charge of British company news and before that was posted to Johannesburg, covering the economic challenges facing post-apartheid South Africa."
    • More from Ben

    • Follow Ben